Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
NantHealth operates a cloud-based healthcare information platform providing clinical decision support, molecular profiling, and data analytics primarily for oncology and complex disease management. The company faces severe financial distress with negative working capital ($0.35 current ratio), massive operating losses (-76.6% margin), and near-zero market capitalization, indicating potential delisting or restructuring risk. Revenue base is minimal at $100M with limited growth momentum (6.9% YoY) while cash burn continues unabated.
NantHealth monetizes proprietary healthcare data infrastructure through recurring SaaS contracts with hospitals, oncology centers, and health systems. The 57% gross margin suggests reasonable unit economics on software delivery, but the -76.6% operating margin reveals unsustainable overhead structure relative to revenue scale. The business model depends on converting clinical data into actionable insights, but limited pricing power is evident given minimal revenue base despite years of operation. Competitive advantage appears eroded as larger EMR vendors (Epic, Cerner/Oracle) integrate similar decision support capabilities natively.
Liquidity events or financing announcements (equity raises, debt restructuring, strategic partnerships) given critical cash position
Customer contract wins or losses, particularly large health system deployments that materially impact revenue trajectory
Regulatory developments in healthcare data interoperability (21st Century Cures Act implementation, TEFCA framework) affecting platform adoption
Delisting warnings or compliance issues given near-zero market cap and likely failure to meet exchange minimum requirements
Healthcare data interoperability mandates (FHIR standards, USCDI requirements) commoditize proprietary data integration capabilities, reducing differentiation versus open-source or low-cost alternatives
Large EMR vendors (Epic, Oracle Health, Meditech) vertically integrate clinical decision support and analytics natively, eliminating need for third-party platforms like NantHealth
AI-powered clinical decision support from tech giants (Google Health, Microsoft Azure Healthcare APIs) threatens to obsolete legacy rule-based systems with superior predictive accuracy
Established competitors (IBM Watson Health assets now owned by Francisco Partners, Tempus AI in oncology analytics) have significantly larger customer bases and R&D budgets
Customer concentration risk likely severe given small revenue base - loss of any major account could trigger 10-20%+ revenue decline
Inability to invest in product development due to cash constraints creates widening technology gap versus well-funded competitors
Imminent liquidity crisis with $0.35 current ratio indicating inability to meet short-term obligations without emergency financing
Negative equity position suggests accumulated losses exceed total assets, making equity raises massively dilutive to existing shareholders
Potential going concern qualification from auditors if cash runway falls below 12 months, triggering covenant violations or accelerated debt repayment
Delisting risk from major exchanges due to sub-$50M market cap and likely failure to maintain minimum bid price requirements
moderate - Healthcare IT spending exhibits relative stability during recessions as hospitals prioritize operational efficiency and regulatory compliance. However, discretionary technology projects face budget scrutiny during economic downturns, and NantHealth's weak competitive position makes it vulnerable to customers consolidating vendors. The company's financial distress amplifies cyclical risk as capital markets tighten during recessions, limiting refinancing options.
Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly severe for near-zero market cap equities; (2) Increased financing costs for any debt restructuring or working capital facilities; (3) Hospital customers face higher borrowing costs for capital projects, potentially delaying IT infrastructure investments. The company's negative equity position (-1.19 D/E ratio) suggests existing debt is underwater, making refinancing extremely challenging in higher-rate environments.
Critical - The company's survival depends entirely on access to capital markets or strategic financing. With negative working capital and ongoing cash burn, NantHealth requires continuous external funding. Tightening credit conditions would likely trigger bankruptcy or forced asset sale. The -217.9% ROA indicates the company is destroying capital at an unsustainable rate.
Speculative distressed/turnaround investors or bankruptcy arbitrageurs given the severe financial distress. The stock functions as a lottery ticket on potential restructuring, strategic acquisition, or unexpected contract wins. Traditional growth or value investors avoid due to lack of profitability path and balance sheet insolvency. Extremely high-risk profile suitable only for investors comfortable with total capital loss.
high - Micro-cap stocks with existential financial challenges exhibit extreme volatility driven by low liquidity, wide bid-ask spreads, and binary outcomes (financing success/failure, delisting events). Any material news (contract wins, financing announcements, restructuring rumors) can move the stock 20-50%+ intraday. Beta likely exceeds 2.0x with significant idiosyncratic risk uncorrelated to broader market movements.